[go: up one dir, main page]

WO2007104263A8 - 一种乙型肝炎病毒疫苗增效蛋白及其基因 - Google Patents

一种乙型肝炎病毒疫苗增效蛋白及其基因 Download PDF

Info

Publication number
WO2007104263A8
WO2007104263A8 PCT/CN2007/000844 CN2007000844W WO2007104263A8 WO 2007104263 A8 WO2007104263 A8 WO 2007104263A8 CN 2007000844 W CN2007000844 W CN 2007000844W WO 2007104263 A8 WO2007104263 A8 WO 2007104263A8
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
enhancin
gene
vaccine
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2007/000844
Other languages
English (en)
French (fr)
Other versions
WO2007104263A1 (zh
Inventor
Naishuo Zhu
Huaqing Li
Min Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Priority to US12/282,754 priority Critical patent/US8895237B2/en
Priority to JP2008558624A priority patent/JP5097135B2/ja
Publication of WO2007104263A1 publication Critical patent/WO2007104263A1/zh
Anticipated expiration legal-status Critical
Publication of WO2007104263A8 publication Critical patent/WO2007104263A8/zh
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/CN2007/000844 2006-03-16 2007-03-16 一种乙型肝炎病毒疫苗增效蛋白及其基因 Ceased WO2007104263A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/282,754 US8895237B2 (en) 2006-03-16 2007-03-16 Enhancing of hepatitis B virus vaccine and its gene
JP2008558624A JP5097135B2 (ja) 2006-03-16 2007-03-16 Ｂ型肝炎ワクチンの免疫応答を促進するタンパク質およびその遺伝子

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610024756.5 2006-03-16
CNB2006100247565A CN100503827C (zh) 2006-03-16 2006-03-16 一种乙型肝炎病毒疫苗增效蛋白及其基因

Publications (2)

Publication Number Publication Date
WO2007104263A1 WO2007104263A1 (zh) 2007-09-20
WO2007104263A8 true WO2007104263A8 (zh) 2009-07-30

Family

ID=38018117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/000844 Ceased WO2007104263A1 (zh) 2006-03-16 2007-03-16 一种乙型肝炎病毒疫苗增效蛋白及其基因

Country Status (4)

Country Link
US (1) US8895237B2 (zh)
JP (1) JP5097135B2 (zh)
CN (1) CN100503827C (zh)
WO (1) WO2007104263A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106177932A (zh) * 2016-07-03 2016-12-07 查文娟 一种耐甲氧西林金黄色葡萄球菌的疫苗
CN109294968B (zh) * 2017-07-25 2022-06-14 格兰柏生化科技有限公司 一种动物核酸疫苗的大规模生产技术
CN114702573B (zh) * 2022-02-28 2024-04-05 中国科学院生物物理研究所 乙肝病毒表面s蛋白高亲和力纳米抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1682177T1 (sl) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije

Also Published As

Publication number Publication date
CN100503827C (zh) 2009-06-24
JP2009529334A (ja) 2009-08-20
JP5097135B2 (ja) 2012-12-12
US8895237B2 (en) 2014-11-25
CN1948493A (zh) 2007-04-18
WO2007104263A1 (zh) 2007-09-20
US20100055135A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2007024941A3 (en) Polyvalent vaccine
WO2007067681A3 (en) Immunostimulatory compositions and methods
WO2010057159A3 (en) Antigens that elicit immune response against flavivirus and methods of using same
WO2007052163A3 (en) Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
WO2007147529A3 (en) Recombinant viral vaccine
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
EP1917033A4 (en) VIRUS LIKE PARTICLES AS PARAMYXOVIRUS VACCINES
WO2009117656A3 (en) Capsid-incorporated antigen for novel adenovirus vaccine
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2010019262A3 (en) Polyvalent vaccine
CY1112895T1 (el) Μεταβολη της ισορροπιας τη1/τη2 στα διαχωρισμενα αντιγριπικα εμβολια με ανοσοενισχυτικα
MY170659A (en) Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2006110728A3 (en) Immunogenic cmv tegument aggregates
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
WO2007050095A3 (en) Improved vaccines and methods for using the same
WO2007082734A3 (en) Influenza vaccine
WO2007104263A8 (zh) 一种乙型肝炎病毒疫苗增效蛋白及其基因

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07720424

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008558624

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2207/MUMNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12282754

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 07720424

Country of ref document: EP

Kind code of ref document: A1